Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Oxford Immunotec Wins Medical Futures Innovation Award

Oxford, UK; 4 November 2005 - Oxford Immunotec's revolutionary new blood test for diagnosing TB infection, called T-SPOTTM.TB has won the Equinox-sponsored award for the Best Business Proposition at the Medical Futures Innovation Awards 2005.

The test is based on a breakthrough in diagnostic testing that allows the measurement of individual T cells specific to Mycobacterium tuberculosis. T-SPOT.TB was approved for sale in Europe last year. Until recently the only means of testing for TB infection was the 115 year old tuberculin skin test (TST). T-SPOT.TB is the only effective test for the reliable screening and early detection of latent TB infection in immuno-compromised patients and offers a substantially more accurate, effective and efficient tool for identifying and controlling the spread of TB.

The prestigious Medical Futures awards, which this year attracted a record 1,200 entries, were judged by a high-profile panel including Dame Carol Black, the President of the Royal College of Physicians, Professor Aidan Halligan, the NHS Director of Clinical Governance and Harry Cayton, the Department of Health Director of Patients and the Public.

Oxford Immunotec beat selected finalists including entries for a non-invasive fracture fixation system and a hand-held device to measure blood flow problems. The Company's success in winning the Best Business Proposition award underlines the market potential for T-SPOT. TB.

Commenting on the award Dr Peter Wrighton-Smith, Oxford Immunotec's Chief Executive Officer, said, 'We are delighted that we have been selected to receive this prestigious award. As the threat of a TB epidemic looms, this award highlights the need to bring TB testing into the 21st century and is a validation of the commercial value of our revolutionary technology platform.'

About Oxford Immunotec
Oxford Immunotec, the T-Cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT(tm) technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person's cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T-Cell response.

About T-SPOT(tm).TB
T-SPOT.TB is an in vitro T-Cell measurement assay used for diagnosing TB infection and the first product from Oxford Immunotec using the T-SPOT TM technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immuno-compromised patient groups. T-SPOT.TB is approved for sale in Europe and is designed to replace the 115 year old tuberculin skin test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market of 600m.

T-SPOT is a trademark of Oxford Immunotec.

About the Medical Futures Innovations Awards
The Awards, which were set up in 2001 by practicing NHS doctor, Dr Andy Goldberg, are designed to encourage and promote a culture of creativity, innovation and leadership amongst healthcare professionals and facilitate the successful commercialisation of these ideas.

This year the Medical Futures Innovations Awards attracted a record 1,200 entries. The winners, chosen by an illustrious panel of judges, which included Dame Carol Black, President, Royal College of Physicians; Professor Aidan Halligan, Director of Clinical Governance, NHS and Harry Cayton, Director, Patients and the Public, Department of Health, were announced on 3rd November 2005.

Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.